BI Asset Management Fondsmaeglerselskab’s BioCryst Pharmaceuticals BCRX Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35K	Buy	+3,453	New	+$31.2K	﹤0.01%	667

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's BCRX Position: Q2 2026 in Review

BI Asset Management Fondsmaeglerselskab opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 3,453 shares worth $35K. The stake represents ﹤0.01% of the portfolio and ranks #667 among its holdings.

172 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

BI Asset Management Fondsmaeglerselskab held 3,453 shares of BioCryst Pharmaceuticals worth $35K as of Q2 2026.
BioCryst Pharmaceuticals was a new BI Asset Management Fondsmaeglerselskab position in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of BI Asset Management Fondsmaeglerselskab's portfolio in Q2 2026, its #667 holding.
172 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2026, filed 10 Aug 2026.